Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca PLC Add to portfolio

LON100:AZN, Feb 28, 11:45 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Tuesday, December 31


News

AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer

AZN AZN

ZacksDecember 31, 2019, 1:55 PM UTC. AstraZeneca AZN and Merck MRK announced that the FDA has approved their PARP inhibitor, Lynparza, as maintenance treatment for BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) in patients whose disease has progressed at least 16 weeks following first-line platinum-based chemotherapy regimen. With this approval, Lynparza becomes the first PARP inhibitor to be approved for treating biomarker-selected patients with advanced pancreatic cancer. In the first nine months, sales from the drug grew 93% year over year to $847 million on the back of several label expansions, especially first-line ovarian cancer. AstraZeneca expects it to reach blockbuster status this year. Lynparza enjoys advantage in the PARP inhibitor segment as it is approved for the most number of oncology indications. AstraZeneca PLC Price. AstraZeneca PLC price | AstraZeneca PLC Quote.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, December 30


News

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AZN AZN

The U.S. Food and Drug Administration (FDA) approved the drug's use as a first-line maintenance therapy for patients with BRCA gene mutations whose cancer had spread beyond the pancreas and whose tumours did not worsen after chemotherapy of at least 16 weeks, the British drugmaker said on Monday. The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer. The widely expected approval follows a panel recommendation this month after a study showed Lynparza helped pancreatic cancer patients go nearly twice as long without their disease worsening than those who received a placebo. Lynparza became the first marketed PARP drug with a U.S. approval for ovarian cancer in 2014 and is key to AstraZeneca's push in oncology and sustaining the company's turnaround.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment
  • Technology

Tuesday, December 24


News

AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod

AZN AZN

AZN announced that its triple combination therapy, a combination of budesonide, glycopyrronium and formoterol fumarate, has been approved by the National Medical Products Administration of China as maintenance treatment for chronic obstructive pulmonary disease (“COPD”). We note that budesonide is an ICS, glycopyrronium is a long-acting muscarinic antagonist (“LAMA”) and formoterol fumarate is a long-acting beta-agonists (“LABA”) therapy. Data from the ETHOS previously announced showed that PT010 achieved a statistically-significant reduction in the rate of moderate or severe exacerbations in COPD patients compared to Bevespi and PT009. AstraZeneca’s stock has rallied 31.3% this year so far, outperforming the industry’s rise of 11.8%. We remind investors that Glaxo GSK and its partner Innoviva, Inc. INVA also have a triple combination drug (ICS/LAMA/LABA), Trelegy Ellipta, approved for COPD.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, December 23


News

The Zacks Analyst Blog Highlights: JPMorgan, Boeing, NVIDIA, AstraZeneca and GlaxoSmithKline

AZN JPM +5 more AZN JPM AZN GSK GSK NVDA BA

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase JPM, Boeing BA, NVIDIA NVDA, AstraZeneca AZN and GlaxoSmithKline GSK. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. The Zacks analyst believes that decent loan demand, acquisition of InstaMed, opening of new branches and focus on strengthening credit card business will aid financials.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu

AZN AZN

The approval was based on data from registrational phase II DESTINY-Breast01, which evaluated Enhertu in HER2-positive unresectable and/or metastatic breast cancer patients who have received prior treatment with Roche’s RHHBY Herceptin (trastuzumab), Kadcyla (trastuzumab emtansine) or Perjeta (pertuzumab). We remind investors that AstraZeneca acquired joint development and commercialization rights to this promising cancer candidate from Japan’s Daiichi Sankyo in April this year for approximately $6.9 billion. AstraZeneca will have to pay $125 million in milestone payment to Daiichi Sankyo, following the approval. Following the launch of Enhertu, Daiichi Sankyo will recognize future sales of the drug and AstraZeneca will report its share of gross profit margin from the sales in the United States as collaboration revenues. Apart from breast cancer, trastuzumab deruxtecan is also being developed to treat other HER2-expressing cancers including gastric cancer, advanced colorectal cancer and lung cancer. AstraZeneca’s stock has rallied 32.8% this year so far compared with the industry’s rise of 11.8%.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

The AstraZeneca share price – where next?

AZN AZN

The AstraZeneca (LON:AZN) share price has risen by 7.64% over the past month and it’s currently trading at 7739p. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue. According to the company’s analysts, there are certainly reasons to think it will continue to perform well in the year ahead. Interestingly, at its current price, shares in AstraZeneca are trading at a discount of -5.10% to its 52 week high price. The 1-year performance of the shares has been 31.3%. While analyst forecasts can be a useful guide to what City 'experts' think about a stock's near term future, they can be unreliable.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment
News

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

AZN AZN

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”) today announced that Baergic Bio, Inc. (“Baergic”), a newly formed Fortress partner company, has entered into an exclusive worldwide licensing agreement with AstraZeneca for AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”), as well as an agreement with Cincinnati Children’s Hospital Medical Center (“Cincinnati Children’s”) to advance clinical development in select central nervous system (“CNS”) disorders. As part of Baergic’s formation, AstraZeneca will provide exclusive worldwide rights to AZD7325, now known as BAER-101, including clinical data generated to date, and will have an equity position in Baergic. BAER-101 will continue to be evaluated in pre-clinical and clinical settings in areas of unmet need where a selective GABA A PAM has shown evidence to be an impactful therapeutic. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was recently ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period. Fortress is focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited) and St. Jude Children’s Research Hospital. For more information, visit www.fortressbiotech.com. Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context.

Read Full Details

Topics:
  • Business
  • Health
  • Science
  • Technology
  • Financial

Thursday, December 19


News

SK Holdings strengthens partnership with AstraZeneca, a global bio-pharmaceutical company

AZN AZN

SK Holdings CEO, Donghyun Jang met Leif Johansson, Chairman of AstraZeneca on the morning of December 19th at SK's Headquarters in Seoul. The event was attended by Ms. Anna Hallberg, Swedish Minister of Foreign Trade and Korean government officials including Mr. Jeoung Yeol Yu, Industrial Policy Director of MOTIE and Mr. In-Taek Lim, Health Industry Director of MOHW from the Ministry of Health and Welfare and Ministry of Trade, Industry and Energy, as well as leaders from both companies. AstraZeneca is a global bio-pharmaceutical company generating revenue of over $22bn (approximately KRW 26 trillion, by 2018 standard) that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. During the ceremony, Leif Johansson, AstraZeneca Chairman, said, "SK Biotek is a strategic supplier to AstraZeneca and a good example of Korea's high value, high quality manufacturing. Since 2018 we have been working successfully together to deliver life-changing medicines that are fueling growth and contributing value to patients and society. I am proud that AstraZeneca is working with SK Group to support local innovation and high-value exports, and most importantly to address unmet medical needs around the world." SK Holding's CEO Donghyun Jang said, "Since 2018, we have actively sought to create a shared social value by supporting the supply of innovative drugs to patients through this partnership between the two companies".

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, December 18


News

AstraZeneca Recognized as the Best Place to Work in Lebanon, Jordan and Iraq for 2019

AZN AZN

DUBAI, UAE, Dec. 18, 2019 /PRNewswire/ -- AstraZeneca, an English-Swedish multinational pharmaceuticalcompany, has been awarded for the second year in a row the prestigious Best Place To Work certification in Lebanon, Jordan and for the first year in Iraq. It gives us a reason to come to work every day. It also sets the context for our employees' activities and the roles of our teams, partners and other collaborators," said Rami Scandar, Country President Near East Area. "We hire people who share our passion for science and believe that every day they can make a difference – We follow Science, have the drive and determination to meet the needs of patients – We put patients first. "AstraZeneca across the region is an organization that enables and encourages employees to develop their potential in a diverse culture based on trust and integrity," said Hamza Idrissi, Program Manager for the Middle East. AstraZeneca received outstanding scores across several aspects of their workplace where team members are encouraged to grow their careers, contribute with ideas and work hard in keeping AstraZeneca a high-performing and metrics-driven organization.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Monday, December 16


News

Sweden Advanced Facilities Analysis 2019 - British-Swedish Firm AstraZeneca Invested $285 Million in the Stockholm Region

AZN AZN

Dublin, Dec. 16, 2019 (GLOBE NEWSWIRE) -- The "Sweden: Advanced Facilities Analysis 2019" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering. The study is useful for companies seeking to understand the Swedish market and to understand how to locate a regional headquarters in Sweden. The largest investment program in Swedish history creates opportunities for contractors in Sweden, in Europe, and beyond. Advanced Manufacturing Sector In Sweden7.1 FDI in Sweden 7.2 Sweden - Investment Considerations 7.3 Swedish Government Measures to Motivate or Restrict FDI7.4 Construction & Labor Workers, Stockholm, Sweden - 2018/19 7.5 Description of Industry Sectors in Sweden and Companies Needing Construction - Major Companies in Sweden7.6 Economy - Industrial Companies and Construction in Sweden and the Nordic Countries 7.7 Automotive and Manufacturing 7.7.1 Volvo 7.7.2 Volkswagen / Scania AB7.8 Industrial Companies 7.8.1 Electrolux AB7.8.2 Atlas Copco7.9 Telecommunications 7.9.1 Ericsson 7.9.2 Telia Company AB 7.9.3 Tele2 AB 7.9.4 SKF Bearing And Seal Manufacturing 7.9.5 Autoliv 7.9.6 Alfa Laval AB 7.9.7 Hexagon AB 7.9.8 Hasselblad 7.10 Furniture 7.10.1 IKEA 7.11 Sweden Bio-Pharma & Healthcare: 7.11.1 GE Healthcare 7.11.2 GE Healthcare Life Sciences Continues To Invest in Uppsala - $100 Million 7.11.3 British-Swedish Firm AstraZeneca Invested $285 Million in the Stockholm Region 7.11.4 GoCo Health Innovation City 7.11.5 BioLamina / Novo Nordisk 7.11.6 Pfizer 7.12 Data Centers in Sweden 7.12.1 Swedish Government Support for Data Centers 7.12.2 Electricity Tax for Data Centers in Sweden 7.12.3 Facebook 7.12.4 KnCMiner 7.12.5 Hydro66 7.12.6 Amazon to Open Cloud Data Centers in Sweden 7.12.7 Node Pole 7.12.8 Interxion 7.12.9 Getinge AB 7.12.10 Research Centers in Sweden Data Center7.12.11 EcoDataCenter Builds Second Data Centre Site Near Stockholm 7.12.12 Zenuity 7.12.13 IBM Digital Geospatial 8.

Read Full Details

Topics:
  • Business
  • Financial
  • Science